Index

a
2:1 atroventricular block 114–115
evaluation 79, 81
supraventricular tachycardia 111
AAI pacing modes 98–99, 105–106
ablation therapy 221–318
atrial fibrillation 161, 279–299
carina 286, 287
cryoballoons 295–298
drug testing 289–290
history 279–280
left-sided 284–285
mapping 282
post-operative electrograms 288–289
preparation 281
pulmonary vein isolation 281–298
repeat procedures 290–295
right-sided 285–287
substrate modification 298
transseptal puncture 283
atrial flutter 299–318
anterior wall left-sided 315–316
CTI-dependent 303–306
de novo left-sided 316–317
left-sided 309–317
non-CTI-dependent 306–317
peri-mitral 311–313
right-sided 306–309
roof-dependent left-sided 313–315
bypass tracts 241–253
location-based approaches 246–253
mapping 241–246
complications 231
cryo 224, 295–298
direct-current shocks, technology 222
electrical field mapping 228
focal atrial tachycardias 254
intraatrial reentrant tachycardias 156
macroreentrant tachycardias 153, 155
location-based approaches 246–253
mapping 241–246
magnetic field mapping 226–228

Index

ablation therapy (Continued)
  mapping systems 225–231
  noncontact mapping 228–230
  principles 34–35
  radiofrequency energy
    complications 231
    technology 223–224
  supraventricular tachycardia
    233–254
  atrioventricular junction
    233–234
  atrioventricular node reentry
    234–241
  bypass tracts 241–253
  focal atrial tachycardias 254
  technology 221–224
  ventricular tachycardia 209,
    255–278
  activation mapping
    256–258, 270
  bundle branch reentry
    264–266
  complications 277
  epicardial sinus 259,
    276–278
  hemodynamically
    non-tolerated 274–277
  idiopathic left ventricular
    tachycardia 262–264
  non-ischemic
    cardiomyopathies 275–276
  outflow tract anatomy
    258–259
  pace mapping 258, 271–274
  structural heart disease
    266–274
  accelerated junction tachycardia,
    atrioventricular node
    ablation 240

accuracy, radiofrequency ablation
  224
N-acetylprocainamide 29
action potentials
  see also electrical impulses
  afterdepolarization 21–23
  antiarrhythmic drugs 5,
    25–29
  automaticity 8–9
  AV node 4–5, 8–9
  bradyarrhythmias 14–16
  cardiac anatomy 3–12
  depolarization 6–7, 11
  ECG correlation 11–12, 43
  generation 5–11
  para/sympathetic regulation
    11
  phases 6–9
  propagation 3–5, 7, 11–12
  refractory period 6, 7–8
  repolarization 7–8, 12
  resting phase 8–9
  SA node 3–4, 9
  shapes 5, 9–12, 25–27
  tachyarrhythmias 16–17
  activation mapping
    focal atrial tachycardias 254
    ventricular tachycardia
      256–258, 270
  AFFIRM trial 162–163
  afterdepolarization
    delayed 200–202
    early 197–200
    triggered activity 21–23
  AH intervals, principles 50,
    54–55
  ambulatory monitoring, syncope
    337, 344
  amiodarone 28, 29, 32–33, 204,
    207–208
anatomic approach, reentrant atrioventricular node ablation 240
anatomy
atrioventricular node 4–5, 234–238
bundle of His 4–5
cardiac 3–5, 11
CTI-dependent flutter 299–302
sinoatrial node 3–4, 64
anesthesia 47
anterior septal bypass tracts 147–148, 242, 252–253
anterior wall left-sided atrial flutter ablation 315–316
anterograde conduction, bypass tracts 143, 146, 152–153
antiarrhythmic drugs 25–33
atrial fibrillation 160–163
catechol-dependent triggered activity 202
classification 27–29
effects 29–31
inappropriate sinus tachycardia 111
intraatrial reentry 114, 156
macreentrant tachycardia 150
mechanisms 25–27
patient evaluation 61
pause-dependent triggered activity 199
physiological effects 5
proarrhythmia 31–32
pulmonary vein isolation 289–290
reentrant ventricular tachycardias 189–190, 192–194
side effects 34
toxicity 32–33
triggered activity 22–23
vasodepressor syncope 342
ventricular tachycardia 192–194, 199, 202, 217–219, 255
vs. implantable cardioverter–defibrillators 189
withdrawal 33–34
antitachycardia pacing (ATP) 194–196
anxiety management 47
arterial lesion risks 231
A spikes 50, 54–55
atria, electrode placement 48–49
atrial activation, bypass tract-mediated reentry 146–148
atrial fibrillation ablation therapy 279–298
carina 286, 287
catheterization 281–282
cryoballoons 295–298
drug testing 289–290
history 279–280
left-sided 284–285
mapping 282
post-operative electrograms 288–289
preparation 281
pulmonary vein isolation 281–298
repeat procedures 290–295
right-sided 285–287
substrate modification 298
transseptal puncture 283
<table>
<thead>
<tr>
<th>Index</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>atrial fibrillation (Continued)</td>
<td>digitalis toxicity 108–109</td>
</tr>
<tr>
<td>antiarrhythmic drugs 160–163</td>
<td>multifocal 109</td>
</tr>
<tr>
<td>brady-tachy syndrome 65–66</td>
<td>atrial tachycardias, ablation therapy 254</td>
</tr>
<tr>
<td>bypass tracts 151–153</td>
<td>atrioventricular (AV) block</td>
</tr>
<tr>
<td>pacemakers 161</td>
<td>bradycardia</td>
</tr>
<tr>
<td>rate control 161–163</td>
<td>evaluation 75–93</td>
</tr>
<tr>
<td>rhythm control 160–161, 162–163</td>
<td>first-degree 76–77, 83–84</td>
</tr>
<tr>
<td>risk factors 298</td>
<td>His-Purkinje block 76, 85–86</td>
</tr>
<tr>
<td>substrate modifications 298</td>
<td>inapparent disorders 86–93</td>
</tr>
<tr>
<td>atrial fibrosis, brady-tachy syndrome 65–66</td>
<td>nodal block 75–76, 84–85, 86</td>
</tr>
<tr>
<td>atrial flutter</td>
<td>overt disorders 83–86</td>
</tr>
<tr>
<td>ablation therapy 299–318</td>
<td>recording 83</td>
</tr>
<tr>
<td>anterior wall left-sided 315–316</td>
<td>second-degree 77–79, 84–86</td>
</tr>
<tr>
<td>CTI-dependent 303–306</td>
<td>symptoms 75</td>
</tr>
<tr>
<td>de novo left-sided 316–317</td>
<td>third-degree 79–80, 86</td>
</tr>
<tr>
<td>left-sided 309–311</td>
<td>treatment 80–81</td>
</tr>
<tr>
<td>non-CTI-dependent 306–317</td>
<td>classifications 14–16</td>
</tr>
<tr>
<td>peri-mitral 311–313</td>
<td>extrastimulus technique 87–91</td>
</tr>
<tr>
<td>right-sided 306–309</td>
<td></td>
</tr>
<tr>
<td>roof-dependent left-sided 313–315</td>
<td></td>
</tr>
<tr>
<td>bypass tracts 151–153</td>
<td></td>
</tr>
<tr>
<td>CTI-dependent 299–306</td>
<td></td>
</tr>
<tr>
<td>non-CTI-dependent 306–317</td>
<td></td>
</tr>
<tr>
<td>supraventricular tachycardia 114–115, 151–153, 157–159</td>
<td></td>
</tr>
<tr>
<td>atrial muscle, stereotypical action potential 9</td>
<td>atrioventricular (AV) bypass tracts 138–139</td>
</tr>
<tr>
<td>atrial tachycardia</td>
<td>atrioventricular (AV) conduction curves 146–147</td>
</tr>
<tr>
<td>automatic 108</td>
<td>atrioventricular (AV) dissociation 79–80</td>
</tr>
<tr>
<td>Index</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
</tr>
<tr>
<td>atrioventricular (AV) groove</td>
<td>4–5, 138–141, 151</td>
</tr>
<tr>
<td>atrioventricular (AV) nodal reentrant tachycardia</td>
<td>112–114, 129–138</td>
</tr>
<tr>
<td>ablation therapy</td>
<td>234–241</td>
</tr>
<tr>
<td>activation patterns</td>
<td>134–135</td>
</tr>
<tr>
<td>atypical</td>
<td>137</td>
</tr>
<tr>
<td>diagnosis</td>
<td>164–165</td>
</tr>
<tr>
<td>initiation</td>
<td>131–133</td>
</tr>
<tr>
<td>mechanisms</td>
<td>129–131</td>
</tr>
<tr>
<td>myocardial involvement</td>
<td>135–136, 148</td>
</tr>
<tr>
<td>properties</td>
<td>112–113, 136</td>
</tr>
<tr>
<td>P wave/QRS complex relationships</td>
<td>136</td>
</tr>
<tr>
<td>termination</td>
<td>133–134</td>
</tr>
<tr>
<td>treatment</td>
<td>137–138</td>
</tr>
<tr>
<td>atrioventricular (AV) node ablation therapy</td>
<td>233–241</td>
</tr>
<tr>
<td>anatomy</td>
<td>4–5, 234–238</td>
</tr>
<tr>
<td>bradycardia</td>
<td>75–76, 84–85, 86</td>
</tr>
<tr>
<td>extrastimulus technique</td>
<td>87–91</td>
</tr>
<tr>
<td>incremental pacing</td>
<td>91–93</td>
</tr>
<tr>
<td>bypass tracts</td>
<td>138–139, 153–155</td>
</tr>
<tr>
<td>conduction velocities</td>
<td>54–55</td>
</tr>
<tr>
<td>dual pathways</td>
<td>233–238</td>
</tr>
<tr>
<td>electrode placement</td>
<td>50–51</td>
</tr>
<tr>
<td>electrograms</td>
<td>50, 54–55</td>
</tr>
<tr>
<td>first-degree blocks</td>
<td>76–77, 83–84</td>
</tr>
<tr>
<td>heart block</td>
<td>14–15</td>
</tr>
<tr>
<td>Koch's triangle</td>
<td>236–237</td>
</tr>
<tr>
<td>macroreentrant tachycardia</td>
<td>113–114, 148–150</td>
</tr>
<tr>
<td>permanent pacemakers</td>
<td>96</td>
</tr>
<tr>
<td>secondary pacemaker cells</td>
<td>8–9</td>
</tr>
<tr>
<td>second-degree blocks</td>
<td>77–79, 84–86</td>
</tr>
<tr>
<td>slow pathway ablation</td>
<td>237–241</td>
</tr>
<tr>
<td>stereotypical action potential</td>
<td>9</td>
</tr>
<tr>
<td>third-degree blocks</td>
<td>79–80, 86</td>
</tr>
<tr>
<td>automatic atrial tachycardia, properties</td>
<td>108</td>
</tr>
<tr>
<td>automaticity</td>
<td></td>
</tr>
<tr>
<td>antiarrhythmic drugs</td>
<td>29</td>
</tr>
<tr>
<td>bradyarrhythmias</td>
<td>13–14, 66–70</td>
</tr>
<tr>
<td>principles</td>
<td>8–9</td>
</tr>
<tr>
<td>programmed stimulation</td>
<td>44</td>
</tr>
<tr>
<td>tachyarrhythmias</td>
<td>16–17, 53</td>
</tr>
<tr>
<td>automatic supraventricular tachycardia classification</td>
<td>108–111</td>
</tr>
<tr>
<td>inappropriate sinus tachycardia</td>
<td>109–111, 114</td>
</tr>
<tr>
<td>automatic tachyarrhythmia mechanisms</td>
<td>16–17</td>
</tr>
<tr>
<td>automatic ventricular tachyarrhythmia</td>
<td>61, 196–202</td>
</tr>
<tr>
<td>catechol-dependent</td>
<td>61, 200–202, 205</td>
</tr>
<tr>
<td>pause-dependent</td>
<td>197–201</td>
</tr>
<tr>
<td>post-myocardial infarction</td>
<td>196–197</td>
</tr>
<tr>
<td>autonomic tone</td>
<td>AV block diagnosis 81–82</td>
</tr>
<tr>
<td>intrinsic heart rate</td>
<td>73–74</td>
</tr>
<tr>
<td>physiological effects</td>
<td>58</td>
</tr>
<tr>
<td>reentrant arrhythmia effects</td>
<td>61</td>
</tr>
<tr>
<td>AV see atrioventricular</td>
<td>AV intervals, cardiac</td>
</tr>
<tr>
<td>resynchronization therapy</td>
<td>329–330</td>
</tr>
</tbody>
</table>
Index

b

baseline recordings 51–52, 116–117
basic cycle length (BCL) 60
basic protocol 51
Baye’s theorem 185–186
BCL see basic cycle length
β-blockers 61
atrial fibrillation 161
catechol-dependent triggered activity 202
inappropriate sinus tachycardia 111
macroreentrant tachycardia 148, 153
principles 29
sinoatrial node reentrant tachycardia 114
ventricular tachycardias 202, 204, 219
bilateral fascicular block 96
binding, Class I drugs 25–27
bipolar recording configuration 42
blanking periods, pulmonary vein isolation 291
Bovie machines 223
bradyarrhythmias 13–16, 63–106
atrioventricular conductivity 75–93, 335
distal block 76–79, 81
disturbance sites 75–79, 81–83
extrastimulus technique 87–91
first-degree block 76–77, 83–84
incremental pacing 91–93
second-degree 77–79, 84–86
third-degree 79–80, 86
bundle branch block 93–97
cardiac resynchronization therapy 95, 97, 100–101
His–Purkinje system 76, 85–86, 93–96
impulse generation 13–14
impulse propagation 14–16
intraventricular conduction delay 94
mechanisms 13–16
Mobitz-type I blocks 77–79, 84–86
Mobitz-type II blocks 77–79, 85–86
permanent pacemakers 96–106
complications 101–105
decisioning 81, 105–106
major indications 96–97
modes 98–101
nomenclature 97
sinoatrial node 64–74, 334–335
dysfunctions 64–66
interpretation 74
SACT 70–73
SNRT 66–70
syncope 334–335
brady-tachy syndrome 64, 65–66
Brugada syndrome 204–205
bundle branch block 93–97, 148, 202–204
Mahaim tracts 248–250
posterior septal bypass tracts 251
reentrant ventricular tachycardia 264–266
bundle of His anatomy 4–5
electrode placement 50–51
bypass tract-mediated macroreentrant tachycardia 113–114, 138–155
ablation therapy 241–253
location-based approaches 246–253
mapping 241–246
activation patterns 146–148
atrial flutter and fibrillation 151–153
atrioventricular node diagnosis 118, 146–148, 151, 164, 165
initiation 143–146
mechanisms 138–143
myocardial involvement 148
preexcitation 139–141
P wave/QRS complex relationships 143–144, 148
termination 146
treatment 148–155
bypass tracts anterior septal 147–148, 242, 252–253
anterograde conduction 143, 146, 152–153
atrioventricular nodal characteristics 241
concealed 143–146
delta waves 242–243
fasiculoventricular 154

intracardiac electrograms 244–246
left-sided 147, 242, 246–247
Mahaim-type 138–139, 154, 248–250
midseptal 242, 252–253
multiple 154–155
posterior septal 242, 250–251
properties 138–141, 151
retrograde conduction 143–148, 150
right-sided 147, 242, 247–248
surgical treatment 155, 241–253

c calcium blockers atrial fibrillation 161
inappropriate sinus tachycardia 111
calcium ion channels antiarrhythmic drugs 25–29
automaticity 8–9
depolarization 5, 6–7
cardiac action potentials 5–12
afterdepolarization 21–23
antiarrhythmic drugs 25–29
automaticity 8–9
bradyarrhythmias 14–16
depolarization 6–7, 11
ECG correlation 11–12
generation 5–11
para/sympathetic regulation 11
phases 6–9
propagation 3–5, 7, 11–12
repolarization 7–8, 12
resting phase 8–9
shapes 5, 9–12, 25–27
tachyarrhythmias 16–17
Index

cardiac anatomy 3–5, 11
cardiac Arrhythmia Suppression Trial (CAST) 206–207
Cardiac resynchronization therapy (CRT) 95, 97, 319–332
clinical studies 323–326
contractility 322–323
effects 322–323
hemodynamic stabilization 322
implantation 327–328
indications 326–327
optimization 329–331
pacing modes 100–101
principles 320–322
reverse remodeling 323
unresolved issues 328–329
carina, pulmonary vein isolation 286, 287
CARsTO mapping system 226–228, 230
CAST see Cardiac Arrhythmia Suppression Trial
catecholamine-dependent ventricular tachycardia 61, 200–202, 205
catheterization atrial fibrillation ablation 281–282
complications 62
positioning 47–51
radiofrequency ablation 223–224
reentrant supraventricular tachycardia diagnosis 116–117
cavo-tricuspid isthmus (CTI)-dependent flutter 299–306
cellular potentials 5–6
automaticity 8
depolarization 6–7
quiescence 8
refractory period 6–8
repolarization 7–8
resting phase 8–9
chaotic atrial tachycardia see multifocal atrial tachycardia
circuits, reentry 18–21
Class la drugs 27–29
binding 25–27
intraatrial reentry 114, 156
macroeunetral tachycardia 150, 153
Class Ib drugs 29
Class lc drugs 29
inappropriate sinus tachycardia 111
macroeunetral tachycardia 150
Class II drugs 28–29
see also β-blockers
Class III drugs 28–29
Class IV drugs 28–29
Class V drugs 28–29
classifications antiarrhythmic drugs 27–29
automatic supraventricular tachycardia 108–111
heart block 14–16
permanent pacemakers 97
reentrant supraventricular tachycardias 111–116
compact atrioventricular node 233–238
complications 62
direct current ablation 222
implantable cardioverter–
defibrillators 210–211
radiofrequency ablation 231
reentrant atrioventricular nodal
reentrant atrioventricular nodal
treatment 237–238
ventricular tachycardia ablation
277
concealed bypass tracts 143–146
conduction velocities
autonomic tone 58
evaluation 43–45, 54–55,
57–58
functional refractory periods
57
principles 9
reentry 18–21
relative refractory periods 56
sinoatrial node 70–74
supraventricular reentry
118–125
conductivity
anterograde 143, 146, 152–153
AV node and bradycardia
75–93
His bundle evaluation 54–55
reentry 18–21
retrograde 143–148, 150
congenital reentrant pathways 20
construction of electrode catheters
41–42
contractility, cardiac
resynchronization
therapy 322–323
coronary sinus
peri-mitral atrial flutter 311
posterior septal bypass tracts
251
ventricular tachycardia 259
corrected sinus node recovery
time (CSNRT) 69–70
coupling intervals
functional refractory periods
57
principles 40–41
supraventricular tachycardia
120
CRT see cardiac resynchronization
therapy
cryo ablation
atrial fibrillation 295–298
technology 224
CSNRT see corrected sinus node
recovery time
CTI see cavo-tricuspid isthmus
cumulative risk 62
cycle length
principles 40
refractory period effects
57–58
Wenckebach 91
d
DADs see delayed
afterdepolarizations
DC see direct current
DDD pacing modes
decisioning 105–106
inappropriate rate tracking
103
principles 99–100
tachycardia induction
101–103
decisioning
pacemaker choice 81,
105–106
supraventricular tachycardia
testing 163–166
Index

defibrillation 45–46, 47, 187
see also direct current cardioversion
Defibrillator in Acute Myocardial Infarction Trial (DINAMIT) 214–216
degeneration, reentrant ventricular tachycardias 188
delayed afterdepolarizations (DADs) 200–202
delta waves 139–141, 242–243
de novo left-sided atrial flutter 316–317
depolarization see also afterdepolarization
class I drugs 25–29
intracardiac electrogram data 42–43
depressed ejection fractions, reentrant ventricular tachyarrhythmias 173–175
designing treatment plans 354–357
device therapy
atrial fibrillation 161
AV block efficacy 81
cardiac resynchronization 319–332
clinical studies 323–326
effects 322–323
implantation 327–328
indications 326–327
optimization 329–331
principles 320–322
complications 101–105
decisioning 81, 105–106
leadless 104–105
macoreentrant tachycardias 150
principles 35
rate tracking 103
reentrant ventricular tachycardias 194–196
ventricular dyssynchrony 103–104
diagnosis see also differential diagnosis
antiarrhythmic drugs 61
atrioventricular block 75–93
automaticity evaluation 53
bundle branch block 93–97
bypass tracts 241–246, 252–253
cardiac electrophysiology evaluation 52–61
cardiac resynchronization therapy 326–327, 329–331
conduction velocities 54–55, 57–58
cumulative risk 62
equipment 41–42, 45–46
extrastimulus technique 44–45
incremental pacing 44
intrinsic heart rate 73–74
laboratory requirements 45–46
left bundle branch block 95–97
macoreentrant tachycardia 118, 146–148, 151, 164, 165
mapping, principles 60–61
methodology 347–353
pacing 43–45
patient preparation 46–47
permanent pacemakers 96–106
positioning of electrodes 47–51
principles 39–62
programmed stimulation 43–45
recording 43–45, 60–61
reentrant disorders 58–61, 118–125, 146–148, 151
re refractory periods 55–58
right bundle branch block 94–95
sinoatrial node 64–74
syncope 338–341, 342–345
therapeutic end points 353–354
treatment plans 354–357
differential diagnosis
anterior/midseptal bypass tracts 252–253
posterior septal bypass tracts 251
supraventricular tachycardia 118–129, 163–166
ventricular tachycardia 178–179
digitalis 29
atrial fibrillation 161
macro reentrant tachycardia 153
toxicity 108–109, 111
triggered activity 22–23
DINAMIT see Defibrillator in Acute Myocardial Infarction Trial
direct current (DC) ablation, technology 222
direct current (DC) cardioversion 187
see also defibrillation
directionality
ECGs 10, 11–12
intracardiac electro gram data 42
reentry 18–21
dissociation, atrioventricular 79–80
distal heart block 76–79
see also Mobitz-type II blocks
first-degree 83–84
pacemakers 81
dose–response curves, inducibility 191–194
dual atrioventricular nodal pathways 233–238
dual-chambered pacemakers 99–100
“dunk-tank model” 192–194
dysautonomia, inappropriate sinus tachycardia 110–111
dysplasia, right ventricular 203
e
EADs see early afterdepolarizations
early afterdepolarizations (EADs) 197–200
ECG see electrocardiograms
echo zones see tachycardia zones
EEG see electroencephalograms
effective refractory periods (ERP) 56, 58–60, 87–91
electrical field mapping 228
Index

384

electrical impulses

see also action potentials; conduction...

afterdepolarization 21–23
anterograde 143, 146, 152–153
antiarrhythmic drugs 5, 25–29, 61
AV node 3–4
baseline recordings 47, 51–52
bradyarrhythmias 14–16
cardiac anatomy 3–12
depolarization 6–7, 11
ECG correlation 11–12
para/sympathetic regulation 11
physiological evaluation 52–61
propagation 3–5, 7, 11–12
reentry 18–21
refractory period 6, 7–8
repolarization 7–8, 12
resting phase 8–9
retrograde 143–148, 150
SA node 3–4
tachyarrhythmias 16–17
electrical system
ECG correlation 11–12
innervation 11
physiological evaluation 52–61
principles 3–12

electroanatomic mapping systems 225–231
electric field mapping 228
magnetic field mapping 226–228
noncontact systems 228–230
principles 225–226

see also intracardiac

electrograms
action potentials relationship 11–12, 43
atrial fibrillation 114–115, 152, 164
atrial flutter 114–115, 164
atrioventricular node reentry 136, 164
automatic atrial tachycardia 108, 164–165
AV block diagnosis 81
AV node 4–5
baseline recordings 47, 51–52
bradyarrhythmias 14–15
Brugada syndrome 204
bundle branch block 92
bypass tract localization 241–243, 252–253
coupling intervals 40–41
cycle lengths 40
delta waves 139–141, 242–243
directionality 10, 11–12
idiopathic left ventricular tachycardia 202–203
intraatrial reentry 114, 164, 165
multifocal atrial tachycardia 109

pause-dependent ventricular tachyarrhythmias 198–201

PR interval 4–5, 10, 11
P wave 10, 11
QT intervals 10, 12
reentrant ventricular arrhythmias 173–175, 255–256, 266–268
sinoatrial nodal reentry 114, 164, 165
Index

ST segment 10, 12
syncope 343–345
T wave 10, 12
ventricular fibrillation 176
electrode catheters
construction 41–42
insertion and positioning
atrioventricular junction
ablation 233–234
bypass tract ablation 246–253
principles 47–51
reentrant atrioventricular node ablation 237–241
superventricular tachycardias 116–117
electroencephalograms (EEG), syncope 344
electrolyte levels,
pause-dependent triggered activity 197
equipment for studies 41–42, 45–46
equipment for treatment 221–231
ERP see effective refractory periods
escape pacemakers 15
evaluation
antiarrhythmic drugs 61
automaticity 53
baseline recordings 51–52
basic protocol 51
bradycardia 63–106
atrioventricular block
extrastimulus technique 87–91
first-degree 76–77, 83–84
incremental pacing 91–93
second-degree 77–79, 84–86
third-degree 79–80, 86
atrioventricular node 75–93
bundle branch block 93–97
Mobitz-type I block 77–79, 84–85
Mobitz-type II blocks 77–79, 85–86
SACT 70–73, 74
SNRT 66–70, 74
bypass tracts
ablation procedures 246–253
electrocardiograms 241–243
intracardiac electrograms 244–246
cardiac resynchronization therapy 326–327, 329–331
catechol-dependent triggered activity 200–202
clinical methodology 347–353
complications 62
conduction velocities 54–55, 57–58
cumulative risk 62
His bundle conductivity 54–55
intrinsic heart rate 73–74
pause-dependent triggered activity 197–201
reentrant arrhythmias 58–61, 129–196
evaluation (Continued)
  preoperative testing 194–196
  refractory period 55–58
  structural heart disease 353
  supraventricular tachycardia 107–166
    atrial fibrillation 151–153, 159–163, 164
    atrial flutter 151–153, 157–159, 164
    atrioventricular nodal reentry 129–138, 164
    bypass tract-mediated 138–155, 164, 165
    classifications 108–116
    intraatrial reentry 155–156, 164, 165
    invasive testing requirements 163–166
    principles 118–129
    sinoatrial node reentry 156–157, 164, 165
  syncope
    bradyarrhythmias 334–335
    methodologies 338–341, 342–345
    supraventricular tachycardia 335–336
    tilt-table testing 340–341
    vasodepressor 338–342
    ventricular fibrillation 177–179
    ventricular tachycardia 336–338
  therapeutic end points 353–354
  treatment plans 354–357
    ventricular arrhythmias 167–205
    automatic 198–202
  fibrillation 176–180
    functions 180
    inducibility 191–194
    initiation 180–187
    intravenous adenosine 178
    preoperative testing 194–196
    reentrant 169–198
    termination 187–189
    treatment 194–196, 205–220
    unusual 202–205
  evidence-based approaches, ICDs 212–220
  exercise-related syncope 337, 344
    excitability 6, 8–9
    exit block, sinoatrial node 70–73
    extrastimulus technique
      atrioventricular block 91–93
      bypass tract-mediated reentry termination 146
      principles 44–45
      reentrant ventricular tachycardia 181–188

f
  fainting see syncope
  false positives 185–186
  fasciculoventricular bypass tracts 154
  femoral vein catheterization 47–48
  fibrillation
    atrial
      ablation therapy 279–299
      antiarrhythmic drugs 160–163
      brady-tachy syndrome 65–66
Index

diagnosis 114–115, 151–153, 159–160
pacemakers 161
rate control 161–163
rhythm control 160–161, 162–163
supraventricular tachycardia 151–153, 159–163
treatment 160–163
ventricular 168, 176–180, 188
evaluation 168, 176–180, 188
first-degree AV block 14, 76–77, 83–84, 335
flecainide 29, 150, 160
fluoroscopic imaging 48–49
flutter, brady-tachy syndrome 65–66
focal atrial tachycardia ablation 254
FRP see functional refractory periods
functional refractory periods (FRP) 57, 87–88

generation of transmembrane potential 5–11

h
heart block
see also atrioventricular block classifications 14–16
inadvertent 231
permanent pacemakers 96
heart rates, cycle lengths 40
hemodynamically non-tolerated ventricular tachycardia, ablation therapy 274–277
hemodynamic stabilization, cardiac resynchronization therapy 322
h gates 25–29
His bundle
anatomy 4–5
atrioventricular junction ablation 234
bypass tracts 138–139, 252–253
conduction velocity measurement 54–55
electrograms 50, 54–55, 82–93
His–Purkinje system
anatomy 4–5
bradycardia 76, 85–86, 93–96
bundle branch block 93–96
extrastimulus technique 87–88, 90–91
incremental pacing 91
bypass tract/macroreentrant tachycardia 113–114
electrode placement 50–51
first-degree blocks 83
heart block 14–15
Mobitz type II block 85–86
second-degree blocks 85
syncope 335
third-degree blocks 86
H spikes 50, 54–55
HV intervals 50, 54–55

i
ibutilide 160–161
ICD see implantable cardioverter–defibrillators
ICE see intracardiac echocardiography
idiopathic left ventricular tachycardia 202–203, 262–264
IHR see intrinsic heart rate
Immediate Risk Stratification Improves Survival (IRIS) trial 214–216
implantable cardioverter–defibrillators (ICD) 189, 209–220
see also pacemakers
bradyarrhythmias 96–106
Brugada syndrome 204 complications 210–211
evidence-based approaches 212–220
ischemic cardiomyopathy 215, 217–219
non-ischemic cardiomyopathy 216–219
overview 209–210
post-myocardial infarction 215–216
preoperative testing 194–196
primary prevention trials 212–216
programming 210
secondary prevention trials 212–213
subcutaneous 211
vs. antiarrhythmic drugs 189
wireless monitoring 211–212
implantation, cardiac resynchronization therapy 327–328
inapparent disorders 86–93
inappropriate rate tracking 103
inappropriate sinus tachycardia (IST) 109–111, 114
incremental pacing atrioventricular block 91–93
bypass tract-mediated reentry
principles 44
tachycardias 181–188
Wenckebach cycle length 91
infranodal block 81
see also distal block
initiation atrioventricular nodal reentry 131–133
bypass tract-mediated supraventricular reentry 143–146
intraatrial reentrant tachycardia 155–156
macroreentry 143–146
principles 19, 21, 58–59
reentrant ventricular tachycardias 180–187
SA nodal supraventricular tachyarrhythmias 156–157
tachycardia zones 120
triggered activity 22
innervation of parasympathetic/sympathetic fibers 11
insertion of electrodes 47–51
atrioventricular junction ablation 233–234
bypass tract ablation 246–253
principles 47–51
superventricular tachycardias 116–117
interpretation atrioventricular tests 83–93
sinoatrial tests 74
intraatrial conduction intervals 55
intraatrial reentrant tachycardia 114, 155–156, 158, 164, 165
intracardiac echocardiography (ICE) 282
intracardiac electrograms antiarrhythmic drug evaluation 61
baseline recordings 47, 51–52, 116–117
basic protocol 51
bradycardia atrioventricular block 75–93
extrastimulus technique 91–93
first-degree 76–77, 83–84
inapparent disturbances 86–93
Mobitz-type I block 77–79, 84–85
Mobitz-type II block 77–79, 85–86
overt disturbances 83–86
second-degree 77–79, 84–86
third-degree 79–80, 86
bundle branch block 93–96
sinoatrial block interpretation 74
SACT measurement 70–73
SNRT measurement 66–70
bypass tracts 244–246
complications 62
conduction velocities 54–55, 57–58
cumulative risk 62
electrode positioning 47–51
equipment 41–42, 45–46
extrastimulus technique 44–45, 91–93
incremental pacing 44
methodologies 51–61
overdrive suppression 53
pacing 43–45
principles 42–43
recording 60–61
reentrant supraventricular tachycardia 116–159
refractory periods 55–58
intravenous adenosine 178
intraventricular conduction delay (IVCD) 94
intrinsic heart rate (IHR) 73–74
ion channels antiarrhythmic drugs 25–29
automaticity 8–9
depolarization 5, 6–7
IRIS see Immediate Risk Stratification Improves Survival trial
ischemic cardiomyopathy diagnosis 353
implantable cardioverter–defibrillators 215, 217–219
isolated pulmonary veins, repeat procedures 293–295
isoproterenol 152, 181, 183–184
IST see inappropriate sinus tachycardia
IVCD see intraventricular conduction delay

j
Jervell–Lange–Nielson syndrome 202
junction boxes 45

k
Koch's triangle 236–237

l
laboratory requirements 45–46
LBBB see left bundle branch block
leaddless pacemakers 104
lead placement, cardiac
resynchronization therapy 330–331
left atria, electrode placement 48
left bundle branch block (LBBB) 95–97
bundle branch reentry 203–204
Mahaim tracts 248–250
outflow tract ventricular
tachycardia 203
posterior septal bypass tracts 251
left-sided atrial flutter
ablation therapy 309–317
antero wall-related 315–316
de novo 316–317
peri-mitral 311–313
roof-dependent 313–315
left-sided bypass tracts 147, 242, 246–247
left-sided pulmonary vein isolation 284–285
left ventricle outflow tract (LVOT)
anatomy 258–259
mapping 260–261
left ventricles, electrode placement 48, 49–50
left ventricular summit 259
lidocaine 29
localization

atrioventricular conduction disorders 75–86
bypass tracts
electrocardiograms 241–243, 252–253
intracardiac electrogams 244–246
surgical approaches 246–253
reentrant supraventricular circuits 118–125, 146–148, 151

m
macroreentrant tachycardia 113–114, 138–155
see also bypass tract-mediated macroreentrant tachycardia; bypass tracts
ablation therapy 241–253
location-based approaches 246–253
mapping 241–246
activation patterns 146–148
anterograde conduction 143, 146, 152–153
atrial flutter and fibrillation 151–153
atrioventricular node 113–114, 138–139, 148–150
diagnosis 118, 146–148, 151, 164, 165
initiation 143–146
intracardiac electrogams 244–246
localization 118, 146–148, 151
mechanisms 138–143
Index

multiple bypass tracts 154–155
myocardial involvement 148
pacemakers 150
P wave/QRS complex relationships 148
QRS complexes 143–144, 148
retrograde conduction 143–148, 150
termination 146
treatment 148–155
MADIT I/II see Multicenter Automatic Defibrillation Implantation Trials
magnetic field mapping 226–228
Mahaim tracts 138–139, 154, 248–250
mapping
atrial fibrillation ablation 282
bypass tracts
electrocardiograms 241–243
intracardiac electrograms 244–246
electrical field systems 228
focal atrial tachycardias 254
magnetic field systems 226–228
noncontact systems 228–230
principles 60–61
reentrant atroventricular node ablation 238–239
systems 225–231
measurement
atrioventricular block 75–80
conduction velocities 54–55, 57–59
refractory periods 55–58
sinoatrial conduction time 70–73
sinus node recovery time 66–70
ventricular dyssynchrony 331
mechanisms
antiarrhythmic drugs 25–29
atrial flutter/ fibrillation 157–159
atrioventricular nodal reentry 129–131
bradyarrhythmias 13–16
bypass tract-mediated
macroreentry 138–143
intraatrial reentrant tachycardia 155–157
syncope 333–341
tachyarrhythmias 16–23
ventricular tachyarrhythmias 169
metabolic causes 17, 32–33, 197
mexitilene 29
m gates 25–26
midseptal bypass tracts 242, 252–253
mitral valve prolapse 205, 259, 262
Mobitz-type I blocks 77–79, 81–82, 84–85, 91
Mobitz-type II blocks 77–79, 81–82, 85–86
modes of therapeutic pacing 98–101
modified Seldinger technique 47
Multicenter Automatic Defibrillation Implantation Trial (MADIT I/II) 213–215
Multicenter Unsustained Tachycardia Trial (MUSTT) 214–215
multifocal atrial tachycardia 109
multiple bypass tracts 154–155

MUSTT see Multicenter
Unsustained Tachycardia
Trial

myocardial infarctions
automatic ventricular
arrhythmias 196–197
implantable
cardioverter–defibrillator
installation 215–216
risk of reentrant ventricular
tachyarrhythmias 173–174
myocardium
see also ischemic
cardiomyopathy;
nonischemic
cardiomyopathy
secondary pacemaker cells
8–9, 15, 79, 81
structural heart disease
266–274, 353
supraventricular reentrant
tachycardia 135–136, 148
ventricular reentrant
tachyarrhythmias 171–174

nomenclature, permanent
pacemakers 97
noncontact mapping 228–230
noninducibility 184, 191–194
noninvasive differentiation, AV
conduction disorders
81–82
non-ischemic cardiomyopathy
implantable cardioverter–
defibrillators 216–219

reentrant ventricular
tachyarrhythmias
171–174, 275–276
nonpharmacologic therapies
25–33
see also ablation therapy; device
therapy
device therapies 35
reentrant ventricular
tachycardias 194–196
reversible etiologies 33–34
normal sinus rhythm 64
nurses 46

optimization of cardiac
resynchronization
therapy 329–331
outflow tract ventricular
tachycardia 203,
258–262
overdrive suppression 53, 66–70
overt atrioventricular conduction
disturbances 83–86

pacemakers 96–106
see also implantable
cardioverter–
defibrillators; sinoatrial
node
atrial fibrillation 161
atrioventricular dissociation
79–80
atrioventricular junction
ablation 234
bradyarrhythmias 96–106
cardiac resynchronization
therapy 95, 97,
100–101, 319–332
<table>
<thead>
<tr>
<th>Index</th>
<th>393</th>
</tr>
</thead>
<tbody>
<tr>
<td>clinical studies</td>
<td>323–326</td>
</tr>
<tr>
<td>effects</td>
<td>322–323</td>
</tr>
<tr>
<td>implantation</td>
<td>327–328</td>
</tr>
<tr>
<td>indications</td>
<td>326–327</td>
</tr>
<tr>
<td>optimization</td>
<td>329–331</td>
</tr>
<tr>
<td>principles</td>
<td>320–322</td>
</tr>
<tr>
<td>complications</td>
<td>101–105, 210–211</td>
</tr>
<tr>
<td>coupling intervals</td>
<td>40–41</td>
</tr>
<tr>
<td>decisioning</td>
<td>81, 105–106</td>
</tr>
<tr>
<td>distal block</td>
<td>79, 81</td>
</tr>
<tr>
<td>evidence-based approaches</td>
<td>212–220</td>
</tr>
<tr>
<td>indications</td>
<td>96–97</td>
</tr>
<tr>
<td>leadless</td>
<td>104</td>
</tr>
<tr>
<td>macroreentrant tachycardias</td>
<td>150</td>
</tr>
<tr>
<td>modes</td>
<td>98–101, 105–106</td>
</tr>
<tr>
<td>mode switching</td>
<td>103</td>
</tr>
<tr>
<td>nomenclature</td>
<td>97</td>
</tr>
<tr>
<td>overview</td>
<td>209–210</td>
</tr>
<tr>
<td>preoperative testing</td>
<td>194–196</td>
</tr>
<tr>
<td>principles</td>
<td>35</td>
</tr>
<tr>
<td>programming</td>
<td>210</td>
</tr>
<tr>
<td>secondary cells</td>
<td>8–9, 15, 79, 81</td>
</tr>
<tr>
<td>sensitivity</td>
<td>102</td>
</tr>
<tr>
<td>sinus bradycardia</td>
<td>13</td>
</tr>
<tr>
<td>wireless monitoring</td>
<td>211–212</td>
</tr>
<tr>
<td>pacemaker syndrome</td>
<td>101</td>
</tr>
<tr>
<td>pacemaker tachycardia</td>
<td>101–103</td>
</tr>
<tr>
<td>pace mapping, ventricular tachycardia</td>
<td>258, 271–274</td>
</tr>
<tr>
<td>pacing</td>
<td>see also extrastimulus technique; incremental pacing; programmed stimulation</td>
</tr>
<tr>
<td>AAI/VVI modes</td>
<td>98–99</td>
</tr>
<tr>
<td>atrioventricular junction ablation</td>
<td>234</td>
</tr>
<tr>
<td>cardiac resynchronization therapy</td>
<td>95, 97, 100–101, 319–332</td>
</tr>
<tr>
<td>common device modes</td>
<td>98–101</td>
</tr>
<tr>
<td>DDD modes</td>
<td>99–100</td>
</tr>
<tr>
<td>overdrive suppression</td>
<td>53</td>
</tr>
<tr>
<td>principles</td>
<td>43–45</td>
</tr>
<tr>
<td>reentrant arrhythmia evaluation</td>
<td>58–60</td>
</tr>
<tr>
<td>SACT measurements</td>
<td>70–73</td>
</tr>
<tr>
<td>SNRT measurement</td>
<td>68–70</td>
</tr>
<tr>
<td>ventricular tachycardia reentrant induction</td>
<td>180–187</td>
</tr>
<tr>
<td>reentrant termination</td>
<td>187–189</td>
</tr>
<tr>
<td>papillary muscle, ventricular tachycardia</td>
<td>259</td>
</tr>
<tr>
<td>paraseptal bypass tracts</td>
<td>250–251</td>
</tr>
<tr>
<td>parasympathetic signaling</td>
<td>11, 58</td>
</tr>
<tr>
<td>pathways</td>
<td>antiarrhythmic drug effects</td>
</tr>
<tr>
<td>reentry</td>
<td>18–21</td>
</tr>
<tr>
<td>refractory period deviations</td>
<td>58–60</td>
</tr>
<tr>
<td>patients</td>
<td>basic protocol</td>
</tr>
<tr>
<td>catheterization</td>
<td>47–51</td>
</tr>
<tr>
<td>complications</td>
<td>62</td>
</tr>
<tr>
<td>electrocardiogram procedures</td>
<td>51–62</td>
</tr>
<tr>
<td>preparation</td>
<td>46–47</td>
</tr>
<tr>
<td>psychological preparation</td>
<td>47</td>
</tr>
<tr>
<td>serial drug testing</td>
<td>61</td>
</tr>
<tr>
<td>pause-dependent triggered activity, evaluation</td>
<td>197–201</td>
</tr>
<tr>
<td>perforation, risk</td>
<td>231</td>
</tr>
<tr>
<td>Index</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Index</td>
<td></td>
</tr>
<tr>
<td>peri-mitral flutter, ablation therapy</td>
<td>311–313</td>
</tr>
<tr>
<td>permanent pacemakers see cardiac resynchronization therapy; implantable cardioverter-defibrillators; pacemakers personnel requirements</td>
<td>46</td>
</tr>
<tr>
<td>pharmacologic therapies see also antiarrhythmic drugs</td>
<td></td>
</tr>
<tr>
<td>atrial fibrillation 160–163 classification</td>
<td>27–29</td>
</tr>
<tr>
<td>discontinuation</td>
<td>33–34</td>
</tr>
<tr>
<td>effects</td>
<td>29–31</td>
</tr>
<tr>
<td>evaluation</td>
<td>62</td>
</tr>
<tr>
<td>mechanisms</td>
<td>25–27</td>
</tr>
<tr>
<td>patient evaluation</td>
<td>61</td>
</tr>
<tr>
<td>proarrhythmia</td>
<td>31–32</td>
</tr>
<tr>
<td>serial testing</td>
<td>62</td>
</tr>
<tr>
<td>side effects</td>
<td>34</td>
</tr>
<tr>
<td>toxicity</td>
<td>32–33</td>
</tr>
<tr>
<td>phases of cardiac action potentials see depolarization; refractory period; repolarization; resting phase</td>
<td></td>
</tr>
<tr>
<td>phenytin</td>
<td>29</td>
</tr>
<tr>
<td>physical setup</td>
<td>41–42, 45–46</td>
</tr>
<tr>
<td>polymorphic ventricular tachycardia</td>
<td></td>
</tr>
<tr>
<td>catecholaminergic</td>
<td>61, 200–202, 205</td>
</tr>
<tr>
<td>torsades de pointes</td>
<td>23, 32–33, 197–201</td>
</tr>
<tr>
<td>positioning of electrodes atroventricular junction ablation</td>
<td>233–234</td>
</tr>
<tr>
<td>bypass tract ablation</td>
<td>246–253</td>
</tr>
<tr>
<td>principles</td>
<td>47–51</td>
</tr>
<tr>
<td>reentrant atrioventricular node ablation</td>
<td>238–241</td>
</tr>
<tr>
<td>supraventricular tachycardias</td>
<td>116–117</td>
</tr>
<tr>
<td>posterior septal bypass tracts</td>
<td>242, 250–251</td>
</tr>
<tr>
<td>post-operative electrograms, pulmonary vein isolation</td>
<td>288–289</td>
</tr>
<tr>
<td>post-ventricular atrial refractory period (PVARP)</td>
<td>102–103</td>
</tr>
<tr>
<td>preexcitation, bypass tracts</td>
<td>139–141</td>
</tr>
<tr>
<td>premature impulses reentry initiation</td>
<td>58–59</td>
</tr>
<tr>
<td>interactions</td>
<td>58–60</td>
</tr>
<tr>
<td>termination</td>
<td>59–60</td>
</tr>
<tr>
<td>testing principles</td>
<td>43–44</td>
</tr>
<tr>
<td>premature ventricular complexes (PVCs) see also ventricular tachycardia ablation therapy</td>
<td>255–278</td>
</tr>
<tr>
<td>bundle branch reentry</td>
<td>264–266</td>
</tr>
<tr>
<td>epicardial sinus</td>
<td>259, 276–277</td>
</tr>
<tr>
<td>hemodynamically non-tolerated</td>
<td>274–277</td>
</tr>
<tr>
<td>idiopathic left ventricular tachycardia</td>
<td>262–264</td>
</tr>
<tr>
<td>outflow tract</td>
<td>259–262</td>
</tr>
<tr>
<td>structural heart disease</td>
<td>266–274</td>
</tr>
<tr>
<td>activation mapping</td>
<td>256–258, 270</td>
</tr>
<tr>
<td>anatomical considerations</td>
<td>258–259</td>
</tr>
</tbody>
</table>
Index

non-ischemic cardiomyopathies 275–276
pace mapping 258, 271–274
preoperative testing, reentrant ventricular tachycardias 194–196
preparation of patients 46–47
primary prevention trials, ICDs 212–216
PR intervals
anatomy 4–5, 10, 11
atrioventricular nodal bypass tracts 153
measurement 55
proarrhythmia 31–32, 160–161
programmable stimulators 45
programmed stimulation see also pacing
principles 43–45, 58–60
ventricular arrhythmias 180–190
initiation 180–187
termination 187–189
programming, implantable cardioverter–
defibrillators 210
propafenone 27–29, 150, 160–161
propagation
action potentials 7, 11–12
bradyarrhythmias 14–16
proximity effects, bypass tracts 139–141
psychological preparation of patient 47
pulmonary vein isolation (PVI) 281–298
blanking periods 291
carina 286, 287
cryo ablation 295–298
drug testing 289–290
left-sided 284–285
post-operative electrograms 288–289
preparation 281
repeat procedures 290–295
right-sided 285–287
waiting period 287–289
Purkinje fibres
anatomy 4–5
bundle branch block 93–96
bypass tracts 138–139
His-bundle electrograms 54
Mobitz type II block 76, 85–86
stereotypical action potential 9
PVARP see post-ventricular atrial refractory period
PVCs see premature ventricular complexes
PVI see pulmonary vein isolation
P waves
atrial flutter and fibrillation 114–115, 164
atrioventricular nodal reentry 136
bypass tract-mediated tachycardia 148
intraatrial reentry 114
macroeventrational tachycardia 148
properties 10, 11
q
QRS complexes
anatomy 10, 11–12
atrial flutter and fibrillation 164
atrioventricular nodal reentry 136
QRS complexes (Continued)
  bypass tract-mediated
  tachycardia 143–144, 148
  directionality 10, 11–12
  duration measurement 55
  idiopathic left ventricular
  tachycardia 202–203
  intraatrial reentry 114
  intraventricular conduction
delay 94
  macroreentrant tachycardia
  148
  reentrant ventricular
  tachyarrhythmias
  173–176
  sinoatrial nodal reentry
  114
  ventricular tachycardia
  175–176
QR intervals
  anatomy 10, 12
  catechol-dependent triggered
  activity 202
  pause-dependent ventricular
  tachyarrhythmias
  198–199
  quadripolar electrode catheter
  construction 41–42
  quiescence 8, 10

r
  RACE trial 162–163
  radiofrequency (RF) ablation
  see also ablation therapy
  complications 231
  pulmonary vein isolation
  281–295, 297–298
  technology 223–224
  utilization 224
  rapid sodium channels
  class I drugs 27–29
  depolarization 6–7
  mode of action 25–26
  rate control, atrial fibrillation
  161–163
  rate tracking pacemaker errors
  103
  RBBB see right bundle branch
  block
  reconnected pulmonary vein
  ablation 291–293
  recording
  bipolar configuration 42
  principles 39–45
  reentrant arrhythmias 60–61
  recovery time, sinoatrial node
  66–70
  recurrent arrhythmias, reversible
  etiologies 32–33
  reentrant arrhythmias
  see also macroreentrant
  tachycardia; reentrant
  supraventricular
tachycardia; reentrant
  ventricular tachycardia;
  reentry
  evaluation 58–61, 129–196
  programmed stimulation
  58–60
  recording 60–61
  serial drug testing 61
  reentrant supraventricular
  tachycardia 111–163
  see also atrial fibrillation; atrial
  flutter; macroreentrant
tachycardia
  ablation therapy 233–253
  atrioventricular junction
  233–234
atrioventricular node reentry 234–241
bypass tracts 241–253
bypass tract-mediated 113–114, 138–155, 164, 165
classifications 111–116
diagnosis 116–129, 164–165
electrode insertion 116–117
intraatrial 114, 155–156, 165
localization 118–125, 146–148, 151
SA nodal 114, 156–157, 164, 165
syncope 335–336
reentrant ventricular tachycardia 169–198
ablation therapy 255–277
bundle branch reentry 264–266
complications 277
epicardial sinus 259, 276–277
hemodynamically non-tolerated 274–277
idiopathic left ventricular tachycardia 262–264
non-ischemic cardiomyopathies 275–276
structural heart disease 266–274
activation mapping 256–258, 270
antiarrhythmic drugs 189–190, 192–194
bundle branches 264–266
clinical characteristics 175–180
degeneration 188
diagnostic methodology 180–190
"dunk-tank model" 192–194
 electrocardiograms 173–175, 255–256, 266–268
entrainment mapping 271–274
fibrillation 176–180
idiopathic left ventricular tachycardia 262–264
inducibility 191–194
initiation 180–187
noninducibility 184, 191–194
pace mapping 258, 271–274
preoperative testing 194–196
QRS complexes 173–176
risk factors 171–174
syncope 177–179, 336–338
termination 187–189
treatment 194–196
reentry
antiarrhythmic drugs 29–33, 61
concealed conduction 143–148
conduction delays 118–120
congenital 20
disorder acquisition 20–21
entrainment mapping 271–274
initiation 19, 21, 58–59
mapping, principles 60–61
mechanisms 17–21
pace mapping 258, 271–274
prerequisites 18–19
Index

reentry (Continued) 31–32
proarrhythmia 31–32
supraventricular tachycardia 129–131, 138–143, 155–156
surgical therapies, principles 34–35
syncope 336–337
tachycardia zones 21
termination 20–21, 59–60
ventricular tachycardia 169–198
refractory period
antiarrhythmic drugs 29–32
cycle length effects 57–58
evaluation 55–58
macroreentrant tachycardia 148–150, 152–153
principles 6, 7–8
proarrhythmia 31–32
reentry 18–21
relative refractory periods (RRP) 56, 58–60, 87–88
repeat procedures, atrial fibrillation ablation 290–295
repetitive monomorphic ventricular tachycardia 203
see also outflow tract ventricular tachycardia
repolarization
anatomy 7–8
ECGs 12
resting heart rates 64–65
resting phase
antiarrhythmic drugs 29–30
cellular activity 8–9
resting transmembrane potentials 5
retrograde conduction 143–148, 150
return intervals 71–72
reverse remodeling, cardiac resynchronization therapy 323
reversible etiologies 32–33
RF see radiofrequency
rhythm control 160–161, 162–163
right atria, electrode placement 48
right bundle branch block (RBBB) 94–95, 202–203, 251
right-sided atrial flutter, ablation therapy 306–309
right-sided bypass tracts 147, 242, 247–248
right-sided pulmonary vein isolation 285–287
right ventricle outflow tract (RVOT) 258–260
right ventricles
dysplasia 203
electrode placement 49
risk factors
atrial fibrillation 298
Brugada syndrome 204
direct current ablation 222
radiofrequency ablation 231
reentrant ventricular tachyarrhythmias 171–174
sudden death 172–174, 204–205
roof-dependent left atrial flutter ablation 313–315
RRP see relative refractory periods
Index
399

S
SA see sinoatrial
SACT see sinoatrial conduction time
sawtooth patterns 114–115
scar tissue, reentry 20–21
SCD-HeFT see Sudden Cardiac Death in Heart Failure Trial
secondary pacemaker cells 8–9, 15, 79, 81
secondary prevention trials, ICDs 212–213
second-degree atrioventricular block 14, 15, 77–80, 84–86
sedation 47
sensitivity
pacemakers 102
radiofrequency ablation 224
serial drug testing 61–62
shapes of cardiac action potentials 5, 9–12, 25–27
sick sinus syndrome see sinus bradycardia
side effects, antiarrhythmic drugs 34
signal-averaged electrocardiograms 173–175
sinoatrial conduction time (SACT) 70–73
sinoatrial (SA) node
anatomy 3–4, 64
automaticity 8–9, 66–70
bradyarrhythmias 13–14, 64–65, 73, 96
bradycardia evaluation 64–74
bypass tract proximity effects 139–141
conduction times 70–73
dysfunctions 64–66
exit block 70–73
fibrosis 65
inappropriate sinus tachycardia 110
intrinsic heart rate 73–74
overdrive suppression 53
reentrant tachycardia 114, 156–157, 164, 165
SACT measurement 70–73, 74
SNRT measurement 66–70, 74
tachyarrhythmias 16–17
SNRT see sinus node recovery time (SNRT) 66–70, 74
slow pathway ablation, atrioventricular node 237–241
SNRT see sinus node recovery time
sodium channels
class I drugs 27–29
depolarization 6–7
sotalol 29
structural heart disease
entainment mapping 271–274
evaluation 353
ventricular tachycardia, ablation therapy 266–274
ST segment
anatomy 10, 12
Brugada syndrome 204
studies see also diagnosis; evaluation
amiodarone 207–208
antiarrhythmic drugs 61
studies (Continued)
atrial fibrillation treatments
162–163
atrioventricular block 75–93
automaticity evaluation 53
baseline recordings 51–52, 116–117
basic protocol 51
bradycardia 63–106
bundle branch block 93–96
bypass tracts
electrocardiograms 241–243
intracardiac electrograms 244–246
cardiac electrophysiology evaluation 52–61
cardiac resynchronization therapy 323–326
complications 62
conduction velocities 54–55, 57–58
cumulative risk 62
equipment 41–42, 45–46
extrastimulus technique 44–45
incremental pacing 44
laboratory requirements 45–46
pacing 43–45
patient preparation 46–47
positioning of electrodes 47–51
principles 39–62
programmed stimulation 43–44
psychological preparation 47
recording 39–45, 60–61
reentrant disorders, principles 58–60
refractory periods 55–58
sinoatrial disorders 64–74, 334–335
supraventricular tachycardia 107–166
subcutaneous implantable cardioverter–defibrillators 211
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) 214–215
sudden death
atrioventricular junction ablation 234
preventative treatment plans 356–357
risk factors 172–174
"survivors" 177–178
syncope 334–335, 336–337, 344–345
ventricular arrhythmias 167–169, 172–173, 204–205
sudden unexpected nocturnal death syndrome (SUNDS) 204
SUNDS see sudden unexpected nocturnal death syndrome
superior vena cava, anatomy 3–4
supraventricular tachycardia 107–166
see also atrial fibrillation; atrial flutter
ablation therapy 233–254
atrioventricular junction 233–234
atrioventricular node reentry 234–241
bypass tracts 241–253
focal atrial tachycardia 254
antiarrhythmic drugs 111
atrioventricular node reentrant 112–113, 129–138
activation patterns 134–135
diagnosis 164–165
initiation 131–133
mechanisms 129–131
properties 129–131, 136
P wave/QRS complexes 136
termination 133–134
treatment 137–138
automatic, classification 108–111
bypass tract-mediated 113–114, 138–155
activation patterns 146–148
diagnosis 118, 146–148, 151, 164, 165
initiation 143–146
localization 118, 146–148, 151
mechanisms 138–143
termination 146
treatment 148–155
conduction delays 118–125
coupling intervals 120
differential diagnosis 163–166, 178–179
digitalis toxicity 108–109
electrode insertions 116–117
evaluation classifications 108–116
differential diagnosis 163–166
principles 118–129
inappropriate sinus tachycardia 109–111
intraatrial reentry 114, 155–156
intravenous adenosine 178
mechanisms 129–131, 138–143, 155–156
multifocal atrial tachycardia 109
reentrant 111–163
atrial fibrillation 114–115, 151–153, 159–163, 164
AV nodal 112–113, 164–165
bypass-tract mediated 113–114, 164, 165
classification 111–116
general diagnostic principles 116–129
intraatrial 114, 155–156, 164, 165
localization 118–125, 146–148, 151
myocardial involvement 135–136, 148
SA nodal 114, 156–157, 164, 165
sinoatrial node reentrant 114, 156–157, 164, 165
syncope 335–336
treatment atrial fibrillation 160–163
atrial flutter 159
atrioventricular node reentrant 137–138
inappropriate sinus 111
macreentrant circuits 148–155
sinoatrial nodal 157
surgical therapies complications 104–105
surgical therapies (Continued)
  macroreentrant
    supraventricular
      tachycardia 155
      principles 34–35
  sympathetic fibers, innervations
    11
  sympathetic signaling, conduction
    velocities 58
  symptom relief, treatment plans
    355–356
  symptoms, atrioventricular block
    75
  syncope 333–345
    bradyarrhythmias 334–335
    brady-tachy syndrome 66
    causes 333–342
  electrocardiograms 343–345
  electroencephalograms 344
  evaluation, ventricular
    fibrillation 177–179
  permanent pacemakers 96
  sudden death 334–335,
    336–337, 344–345
  supraventricular tachycardia
    335–336
  tachyarrhythmias 335–338
  tilt-table testing 340–341
  vasodepressor 338–342
  ventricular tachycardia
    336–338

  tachyarrhythmias 16–23,
    107–220
  see also supraventricular
    tachycardia; ventricular
    tachycardia
  afterdepolarization 21–23
  automaticity 16–17, 53
  mechanisms 16–23
  metabolic causes 17
  pacemaker-related 101–103
  reentry mechanisms 17–21
  syncope 335–338
  triggered activity 21–23
  tachycardia zones 21, 118, 120
  see also localization
  technology, ablation therapy
    221–224
  termination
    atrioventricular node
    supraventricular
      tachycardia 133–134
    bypass tract-mediated
      supraventricular
      tachycardia 146
    principles 20–21, 59–60
    sinoatrial nodal supraventricular
      tachyarrhythmias 157
    ventricular tachycardias
      187–189
  testing see diagnosis; evaluation;
    studies
    therapeutic end points 353–354
  third-degree atrioventricular block
    14, 15, 79–80, 86
  tilt-table testing 340–341, 344
  time measurement principles
    39–41
  tissue contact, radiofrequency
    ablation 224
  tocainide 29
  torsades de pointes 23, 32–33,
    197–201
  toxicity
    antiarrhythmic drugs 32–33
    digitalis 108–109, 111
  transcatheter ablation 221–318
  see also ablation therapy
atrial fibrillation 279–299
atrial flutter 299–318
complications 231
cryo, technology 224
direct-current shocks, technology 222
electrical field mapping 228
intraatrial reentrant tachycardia 156
magnetic field mapping 226–228
mapping systems 225–231
noncontact mapping 228–230
radiofrequency energy complications 231
technology 223–224
supraventricular tachycardia 233–254
technology 221–224
ventricular tachycardia 255–278
transitional zone, atrioventricular node 233–238
transmembrane potentials antiarrhythmic drugs 25–27
depolarization 6–7
generation 5–11
repolarization 7–8
resting 5, 8–9
transseptal puncture, atrial fibrillation 283
treatment
ablation therapy 221–318
atrial fibrillation 279–299
carina 286, 287
cryoballoons 295–298
drug testing 289–290
history 279–280
left-sided 284–285
mapping 282
post-operative electrograms 288–289
preparation 281
pulmonary vein isolation 281–298
repeat procedures 290–295
right-sided 285–287
substrate modification 298
transseptal puncture 283
atrial flutter 299–318
anterior wall left-sided 315–316
CTI-dependent 303–306
de novo left-sided 316–317
left-sided 309–317
non-CTI-dependent 306–317
peri-mitral 311–313
right-sided 306–309
roof-dependent left-sided 313–315
mapping systems 226–230
supraventricular tachycardia 233–254
atrioventricular junction 233–234
atrioventricular node reentry 234–241
bypass tracts 241–253
focal atrial tachycardia 254
technology 222–224
ventricular tachycardia 255–278
activation mapping 256–258, 270
treatment (Continued)
bundle branch reentry 264–266
complications 277
epicardial sinus 259, 276–278
hemodynamically non-tolerated 274–277
idiopathic left ventricular tachycardia 262–264
non-ischemic cardiomyopathies 275–276
pace mapping 258, 271–274
structural heart disease 266–274
atrial fibrillation 160–163
cryo ablation 295–298
mapping 282
radiofrequency ablation 281–295, 297–298
atrial flutter 159
CTI-dependent 303–306
non-CTI-dependent 306–317
atrioventricular block 80–81
atrioventricular node reentrant tachycardia 137–138
bradycardia
permanent pacemakers 96–106
complications 101–105
decisioning 81, 105–106
major indications 96–97
modes 98–101, 105–106
rate tracking 103
ventricular dyssynchrony 103–104
cardiac resynchronization 319–332
effects 322–323
implantation 327–328
indications 326–327
optimization 329–331
pacing modes 100–101
principles 95, 97, 320–322
studies 323–326
unresolved issues 328–329
concepts 25–35
focal atrial tachycardias 254
implantable cardioverter-defibrillators 189, 209–220
bradyarrhythmias 96–106
Brugada syndrome 204
complications 210–211
evidence-based approaches 212–220
ischemic cardiomyopathy 215, 217–219
non-ischemic cardiomyopathy 216–219
overview 209–210
post-myocardial infarction 215–216
preoperative testing 194–196
primary prevention trials 212–216
programming 210
secondary prevention trials 212–213
subcutaneous 211
vs. antiarrhythmic drugs 189
wireless monitoring 211–212
inappropriate sinus tachycardia 111
macroreentrant
supraventricular tachycardia 148–155, 241–253
nonpharmacologic principles 33–35
pharmacologic therapies 25–33
classification 27–29
effects 29–32
mechanisms 25–27
proarrhythmia 31–32
toxicity 32–33
plans 354–357
sinoatrial nodal supraventricular tachyarrhythmias 157
sudden death prevention 356–357
symptom relief 355–356
therapeutic end points 353–354
vasodepressor syncope 338–342
ventricular tachycardia 194–196, 205–220, 255–278
treatment plans 354–357
triggered activity 197–202
antiarrhythmic drugs 32
catechol-dependent ventricular arrhythmia 61, 200–202, 205
concepts 21–23
pause-dependent ventricular arrhythmias 197–201
syncpe 335–336
torsades de pointes 23, 32–33, 197–201
TU wave abnormalities 199–201
T waves 10, 12

U
underlying causes
pause-dependent triggered activity 197–198
reversal 32–33
units 39

V
valve prolapse, mitral 205, 259, 262
vasodepressor syncope 338–342
V deflections 50, 54–55
vein catheterization 47–48
vena cava 3–5
ventricles
bypass tract-mediated reentry 146–148
electrode placement 48–49
heart block 14–15
ventricular arrhythmia see ventricular fibrillation;
ventricular tachycardia
ventricular dyssynchrony
bundle branch block 93–97, 148, 202–204, 248–250
cardiac resynchronization therapy 95, 97, 100–101, 103–104, 319–332
effects 322–323
implantation 327–328
indications 326–327
optimization 329–331
pacing modes 100–101
principles 320–322
studies 323–326
unresolved issues 328–329
ventricular dyssynchrony
(Continued)
idiopathic left-sided 202–203
left bundle branch block 95–97, 203–204
Mahaim tracts 248–250
measurement 331
right bundle branch block 202–203
right-sided dysplasia 203
ventricular escape mechanisms 15
ventricular fibrillation 168, 176–180, 188
clinical characteristics 176–180
electrocardiograms 176
syncope 177–179
ventricular muscles, stereotypical action potential 9
ventricular tachycardia 167–220
see also premature ventricular complexes
ablation therapy 209, 255–278
bundle branch reentry 264–266
complications 277
epicardial sinus 259, 276–278
hemodynamically non-tolerated 274–277
idiopathic left ventricular tachycardia 262–264
non-ischemic cardiomyopathies 275–276
structural heart disease 266–274
activation mapping 256–258, 270
amiodarone 204, 207–208
antiarrhythmic drugs 255
“conventional” treatment 217–219
reentrant conditions 189–190, 192–194
triggered activity 199, 202
vs. implantable cardioverter–defibrillators 189
automatic 196–202
catechol-dependent 61, 200–202, 205
evaluation 196–202
pause-dependent triggered 197–201
Brugada syndrome 204–205
bundle branch block 202–204
catechol-dependent triggered activity 61, 200–202, 205
clinical characteristics 175–176
degeneration 188
differential diagnosis 178–179
entainment mapping 271–274
epicardial sinus 259, 276–278
evaluation 167–205
automatic 196–202
fibrillation 176–180
functions 180
inducibility 191–194
reentrant 169–198
unusual 202–205
evidence-based approaches 212–220
Index

fibrillation 168, 176–180, 188
idiopathic left-sided 202–203
implantable cardioverter–
defibrillators 189,
209–220
complications 210–211
evidence-based approaches 212–220
overview 209–210
preoperative testing 194–196
programming 210
subcutaneous 211
wireless monitoring 211–212
inducibility 191–194
initiation, reentrant 180–187
initiation of reentry 180–187
intravenous adenosine 178
mechanisms 169
mitral valve prolapse 205
noninducibility 184, 191–194
outflow tract tachycardias 203
QRS complexes 175–176
reentrant 180–194
antiarrhythmic drugs 189–190, 192–194
"dunk-tank model" 192–194
inducibility 191–194
initiation 180–187
preoperative testing 194–196
termination 187–189
treatment 194–196
repetitive monomorphic 203
right-sided dysplasia 203
right ventricular dysplasia 203
risk factors 171–174
sudden death syndromes 167–169, 172–173,
204–205
syncope 336–338
termination 187–189
torsades de pointes 23, 32–33,
197–201
treatment 205–220
ablation therapy 209
antiarrhythmic drugs 189–190, 192–194, 199,
202, 217–219
implantable cardioverter–
defibrillators 209–220
preoperative testing 194–196
principles 206–209
underlying causes 197–198
verapamil 153
visibility, bypass tracts 138
VV intervals
cardiac resynchronization
therapy 330
decisioning 105–106
inappropriate rate tracking
103
principles 98–99

W
Wenckebach cycle length 91, 240
wireless monitoring, implantable cardioverter–
defibrillators 211–212
withdrawal, antiarrhythmic drugs 33–34
Wolff–Parkinson–White
syndrome 139–141